Lung cancer
1L metastatic/recurrent NSCLC1
Lung cancer
1L metastatic/recurrent NSCLC1
1L, first-line; IV, intravenous; NSCLC, non-small cell lung cancer; PD, progressive disease; QxW, every x weeks.
1. Opdivo® (nivolumab). Hong Kong Prescribing Information; Hong Kong: Bristol-Myers Squibb; 2023.